W. H. Houtum, L. A. Lavery, and L. B. Harkless, The impact of diabetes-related 2 lower-extremity amputations in The Netherlands, J Diabetes Complications, vol.10, pp.325-330, 1996.

W. A. Davis, P. E. Norman, D. G. Bruce, and T. M. Davis, , 2006.

, Fremantle Diabetes Study. Diabetologia, vol.49, pp.2634-2641

F. R. Martinez-de-jesus, A checklist system to score healing progress of diabetic 7 foot ulcers, Int J Low Extrem Wounds, vol.9, pp.74-83, 2010.

J. B. Sharefkin and W. Silen, Diuretic agents: inciting factor in nonocclusive 9 mesenteric infarction, JAMA, vol.229, pp.1451-1453, 1974.

D. A. O'rourke and J. E. Hede, Reversible leg ischaemia due to diuretics, Br Med J, vol.1, pp.11-1114, 1978.

B. Neal, V. Perkovic, and K. W. Mahaffey, Canagliflozin and Cardiovascular 13 and Renal Events in Type 2 Diabetes, N Engl J Med, vol.377, pp.644-657, 2017.

J. A. Erkens, O. H. Klungel, R. P. Stolk, J. A. Spoelstra, D. E. Grobbee et al., , 2004.

, Antihypertensive drug therapy and the risk of lower extremity amputations in 16 pharmacologically treated type 2 diabetes patients, Pharmacoepidemiol Drug Saf, vol.13, pp.139-146

T. Gary, K. Belaj, and F. Hafner, Graz Critical Limb Ischemia Score: A Risk 18 Score for Critical Limb Ischemia in Peripheral Arterial Occlusive Disease, Medicine, vol.19, p.1054, 2015.

S. Hadjadj, F. Fumeron, and R. Roussel, Prognostic value of the 21 insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique 1 (SURDIAGENE) studies, Diabetes Care, vol.31, pp.1847-1852, 2008.

A. S. Levey, L. A. Stevens, and C. H. Schmid, A new equation to estimate 3 glomerular filtration rate, Ann Intern Med, vol.150, pp.604-612, 2009.

J. P. Fine, Regression modeling of competing crude failure probabilities, 2001.

, Biostatistics, vol.2, pp.85-97

T. G. Ebrahimian, R. Tamarat, M. Clergue, M. Duriez, B. I. Levy et al., Dual 7 effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice, 2005.

, Arterioscler Thromb Vasc Biol, vol.25, pp.65-70

P. C. Austin, An Introduction to Propensity Score Methods for Reducing the 10 Effects of Confounding in Observational Studies, Multivariate Behav Res, vol.46, pp.399-424, 2011.

A. Officers, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent 12

, Major outcomes in high-risk hypertensive patients randomized to 13 angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The 14, Heart Attack T, 2002.

, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

, JAMA, vol.288, pp.2981-2997

M. J. Brown, C. R. Palmer, and A. Castaigne, Morbidity and mortality in patients 17 randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic 18 in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment 19 (INSIGHT), Lancet, vol.356, pp.366-372, 2000.

I. Tzoulaki, G. D. Murray, A. J. Lee, A. Rumley, G. D. Lowe et al., , 2007.

, Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease

J. A. Udell, Z. Yuan, T. Rush, N. M. Sicignano, M. Galitz et al., , 2018.

, Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2

, Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for

, Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real

, World). Circulation, vol.137, pp.1450-1459

G. P. Fadini and A. Avogaro, SGTL2 inhibitors and amputations in the US FDA, 2017.

, Adverse Event Reporting System, Lancet Diabetes Endocrinol, vol.5, pp.680-681

C. Khouri, J. L. Cracowski, and M. Roustit, SGLT-2 inhibitors and the risk of lower-8 limb amputation: is this a class effect, Diabetes Obes Metab, 2018.

S. Adimadhyam, T. A. Lee, G. S. Calip, S. Marsh, D. E. Layden et al., Schumock GT, vol.10, 2018.

, Inhibitors: A Propensity-Matched Cohort Study, Diabetes Obes Metab, vol.12

Z. Yuan, F. J. Defalco, and P. B. Ryan, Risk of lower extremity amputations in 13 people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors 14 in the USA: A retrospective cohort study, Diabetes Obes Metab, vol.20, pp.582-589, 2018.

K. Radholm, J. H. Wu, and M. G. Wong, Effects of sodium-glucose cotransporter-16 2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes -A 17 systematic review, Diabetes Res Clin Pract, vol.140, pp.118-128, 2018.

G. K. Dawwas, S. M. Smith, and H. Park, Cardiovascular outcomes of sodium glucose 19 cotransporter-2 inhibitors in patients with type 2 diabetes, Diabetes Obes Metab, vol.20, 2018.

H. Y. Chang, S. Singh, O. Mansour, S. Baksh, and G. C. Alexander, , 2018.

, Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among